Brain Tumor News!

Note: The comments under each article title are the opinion of our president, Al Musella, DPM,
and do not reflect official policy of the Musella Foundation!

11/10/06 Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.        

11/10/06 Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.        

11/10/06 Reata Announces Presentation of Interim Results for Phase 1 Study of RTA 744 in Treatment of Advanced Brain Tumors        

11/10/06 Anti-cancer virus kills brain cancer cells        

11/10/06 Jefferson Oncologists Show Less Radiation Just as Effective in Fighting Brain Tumor, Saving Hearing        

11/10/06 Commercial flight and patients with intracranial mass lesions: a caveat. Report of two cases.        

11/10/06 Long-term response of pituitary carcinoma to temozolomide. Report of two cases.        

11/10/06 AACR Science Policy Alert        

11/10/06 A lesson in Living        

11/10/06 Northwest Biotherapeutics Discusses Results From Clinical Trials In Brain Cancer At Two Conferences        

11/10/06 Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas.        

10/31/06 Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma.        

10/30/06 Northwest Biotherapeutics Discusses Results From Clinical Trials in Brain Cancer at Two Conferences        

10/30/06 Mayo Clinic Cancer Center -- Harnessing the Measles Virus to Attack Cancer Seeking a Cure for Glioblastoma Multiforme, Other Deadly Cancers        

10/26/06 Reata Announces Receipt of Orphan Drug Status for RTA 744 in Treatment of Malignant Glioma        

10/18/06 Research Yields Clues to Radiation-Resistant Brain Cancer        

10/17/06 Have a Chance Walk for brain tumors.. NYC Oct 29, 2006        

10/17/06 Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).        

10/17/06 A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.        

---

Displaying Stories 4210 to 4229 of 7812
Previous 20           Next 20